{
  "@context": "https://schema.org",
  "@type": "Organization",
  "name": "Remy Research",
  "legalName": "Remedium Research",
  "alternateName": ["Remy Research", "RemyResearch", "Remy Research Desk"],
  "url": "https://remyresearch.com",
  "logo": "https://remyresearch.com/favicon.svg",
  "image": "https://remyresearch.com/assets/coa/research-reta-20mg-pen/janoshik-ret-20-c-2604-001-purity-1100.jpg",
  "description": "Independent research and COA-verification desk for the reta peptide cluster. Publishes Janoshik Analytical HPLC Certificates of Analysis, GLP-1 / GIP / glucagon triagonist comparisons, and free dose-math tools. No commerce, no order intake. For in-vitro laboratory research only.",
  "foundingDate": "2025",
  "foundingLocation": {
    "@type": "Place",
    "name": "Dubai, UAE"
  },
  "parentOrganization": {
    "@type": "Organization",
    "name": "Remy Peptides",
    "url": "https://remypeptides.com"
  },
  "contactPoint": {
    "@type": "ContactPoint",
    "contactType": "research inquiries",
    "url": "https://remypeptides.com/contact-verify/",
    "availableLanguage": ["English", "Arabic"]
  },
  "knowsAbout": [
    "reta peptide research",
    "reta LY-3437943",
    "GLP-1 / GIP / glucagon triagonist mechanism",
    "Tirzepatide comparison",
    "Cagrisema comparison",
    "Survodutide comparison",
    "Orforglipron comparison",
    "Janoshik Analytical HPLC verification",
    "Certificate of Analysis interpretation",
    "HPLC purity",
    "peptide assay quantification",
    "heavy metals testing",
    "TFA residual solvent testing",
    "bacterial endotoxin (LAL) testing",
    "dose-titration scheduling",
    "pen clicks to mg conversion"
  ],
  "sameAs": [
    "https://remypeptides.com",
    "https://www.instagram.com/remypeptides",
    "https://www.tiktok.com/@remypeptides",
    "https://www.linkedin.com/company/remypeptides",
    "https://www.trustpilot.com/review/remypeptides.com"
  ],
  "compliance": "All material is for in-vitro laboratory research only. Not for human or veterinary use. Remy Research does not make therapeutic, treatment, cure, diagnostic, human-dosing, or veterinary-use claims.",
  "subjectOf": [
    {
      "@type": "Dataset",
      "name": "Batch RET-20-C-2604-001 — Reta 20mg Pen",
      "url": "https://remyresearch.com/coa/ret-20-c-2604-001/",
      "description": "Janoshik Analytical HPLC report: 99.841% HPLC purity at 22.51 mg/mL measured concentration. Task 150762, verification key APSLYZGYW4KA. Analyzed 2026-04-23.",
      "creator": {
        "@type": "Organization",
        "name": "Janoshik Analytical",
        "url": "https://janoshik.com"
      },
      "identifier": "150762"
    },
    {
      "@type": "Dataset",
      "name": "Batch RET-20-V-2604-001 — Reta Vial Line",
      "url": "https://remyresearch.com/coa/ret-20-v-2604-001/",
      "description": "Janoshik Analytical full sterility-grade panel: 99.741% HPLC, 20.92 mg assay, heavy metals not detected, TFA not detected, endotoxin 1.449 EU/Vial. Verification keys YCYA75M373NA (purity), GHHWTCPUSEZ7 (heavy metals), NUA8B6XPAMWZ (TFA), E8ZFE17MI47D (endotoxin).",
      "creator": {
        "@type": "Organization",
        "name": "Janoshik Analytical",
        "url": "https://janoshik.com"
      }
    },
    {
      "@type": "Dataset",
      "name": "Batch RETP002 — Reta 30mg Pen Flagship",
      "url": "https://remyresearch.com/coa/retp002/",
      "description": "Janoshik Analytical HPLC report: 99.262% HPLC purity. Flagship 30mg pen reference, 300 clicks at 0.1 mg per click. Analyzed 2025-11-04.",
      "creator": {
        "@type": "Organization",
        "name": "Janoshik Analytical",
        "url": "https://janoshik.com"
      }
    }
  ],
  "mentions": [
    {
      "@type": "Thing",
      "name": "Reta (LY-3437943)",
      "description": "GLP-1 / GIP / glucagon receptor triagonist, CAS 2381089-83-2, Eli Lilly Phase 3 (TRIUMPH programme)."
    },
    {
      "@type": "Thing",
      "name": "Tirzepatide (LY-3298176)",
      "description": "GLP-1 / GIP dual agonist, CAS 2023788-19-2, Eli Lilly (marketed)."
    },
    {
      "@type": "Thing",
      "name": "Cagrisema",
      "description": "Cagrilintide + Semaglutide co-formulation, Novo Nordisk Phase 3."
    },
    {
      "@type": "Thing",
      "name": "Survodutide (BI 456906)",
      "description": "GLP-1 / glucagon dual agonist, Boehringer Ingelheim Phase 3."
    },
    {
      "@type": "Thing",
      "name": "Orforglipron (LY-3502970)",
      "description": "Oral small-molecule GLP-1 receptor agonist, Eli Lilly (regulatory submission)."
    }
  ],
  "lastUpdated": "2026-05-11"
}